IGF-1/IGFBP3 Prevention of Retinopathy of Prematurity
To compare the severity of retinopathy of prematurity (ROP) among treated infants with an
untreated control population, matched for gestational age at birth while confirming the dose
of rhIGF-1/rhIGFBP-3 is safe and efficacious.
Long-term Safety and Efficacy Outcome Study Comparing Children Previously Enrolled in Study ROP-2008-01 for the Prevention of Retinopathy of Prematurity (ROP)
Active, not recruiting
The main purpose of this study is to evaluate the long-term efficacy and safety outcomes
following short-term exposure to rhIGF-1/rhIGFBP-3 versus standard neonatal care in Study
ROPP-2008-01 (Section D) (NCT01096784).
A Clinical Efficacy and Safety Study of SHP607 in Preventing Chronic Lung Disease in Extremely Premature Infants
Active, not recruiting
The purpose of this study is to determine if an investigational drug can reduce the burden of
chronic lung disease in extremely premature babies through 12 months corrected age (CA), as
compared to extremely premature babies receiving standard neonatal care alone.
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.